Latest from Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute

The presence of metastatic lymph nodes was directly correlated with poorer survival in patients with oral cancer, according to findings published in the Journal of Clinical Oncology.
William Oh, MD, reviews some of the biomarkers under investigation in GU cancers and possibilities for major advances in the field over the next few years.
Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses the current treatment landscape in pancreas cancer.
The addition of pegvorhyaluronidase alfa (PEGPH20) to standard nab-paclitaxel/gemcitabine improved progression-free survival over standard therapy in patients with metastatic pancreatic ductal adenocarcinoma.
Andrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses HALO-202 in metastatic pancreatic ductal adenocarcinoma.
Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology and associate director of academic program development in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses the major novel agents at the forefront of the treatment landscape of renal cell carcinoma.
Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology and associate director of academic program development in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses tyrosine kinase inhibitors that he uses to treat patients with renal cell carcinoma.
Howard M. Sandler, MD, chair, Department of Radiation Oncology, professor of Radiation Oncology, Cedars-Sinai Medical Center, discusses potential combination regimens with chemotherapy as treatment for patients with prostate cancer.
Publication Bottom Border
Border Publication
x